Company intelligence / Profile preview

HealthGene

Ownership: Private
Development stage: Commercial

Overview

The company has completed Phase III clinical trials for plant-derived recombinant human serum albumin in patients with hypoalbuminemia. Results showed non-inferiority to plasma-derived HSA in safety and efficacy. A new drug application is planned, with commercial launch expected soon. Other products are already commercialized as reagents or supplements.

Therapeutic areas: GastroenterologyDermatologyOther
Modalities: Recombinant proteinPeptidesPlant-made pharmaceuticals using rice endosperm expression platform
Industry: Biotech

Beyond the preview

Go deeper on HealthGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HealthGene.

Explore the full profile